Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.26
- Piotroski Score 3.00
- Grade Buy
- Symbol (STOK)
- Company Stoke Therapeutics, Inc.
- Price $12.28
- Changes Percentage (7.68%)
- Change $0.88
- Day Low $11.43
- Day High $12.41
- Year High $17.58
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $28.50
- High Stock Price Target $58.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.42
- Trailing P/E Ratio -6.14
- Forward P/E Ratio -6.14
- P/E Growth -6.14
- Net Income $-104,699,000
Income Statement
Quarterly
Annual
Latest News of STOK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
City of villains: Republicans stoke fears of Democratic-run cities
Atlanta, a political focal point, is unjustly demonized by conservatives for its diversity. Red state governments are stripping power from blue cities to maintain control, driven by fear of demographi...
By The Guardian | 2 days ago -
Ben Stokes confident England have characters who can take the heat
The pressure is on England's inexperienced bowling lineup as they face Pakistan in challenging conditions. With key players missing, the team must rely on new faces to step up....
By The Guardian | 3 days ago -
England captain Ben Stokes to miss first test against Pakistan
England's Ben Stokes will miss the first test against Pakistan due to a torn hamstring. Ollie Pope will lead in his place. Stokes aims to recover for the second test but unsure about bowling....
By AP NEWS | 3 days ago
